Clinical Trial Search

Primary: Percentage of Participants With Febrile Neutropenia — 3.3; 1.9; 0.4; 0.5 percentage of participants

Primary: Chemotherapy Toxicity (%FN Risk) — 154; 650; 640; 3 participants

Primary: Percentage of Participants With Febrile Neutropenia (FN) — 8; 8; 15; 9 percentage of participants

Primary: Percentage of Participants With Any Significant Comorbidities — 42.7 percentage of participants

Primary: Percentage of Investigators Who Ranked Age and Chemotherapy Regimen as a Risk Factor for Febrile Neutropenia — 73.4; 88.3; 41.1; 25.0 percentage of investigators

Primary: Clinical Outcome in the MITT Analysis Set at EOIV. — 44; 37; 5; 12 Participants

Primary: Number of Participants Who Became Afebrile Within 72 Hours of Starting Daptomycin. — 16 participants

Primary: Overall Complete Response Rate — 10; 10 percentage of participants

Primary: Percentage of Participants Receiving Antibacterial Agents Preferred by the Turkish Centers Monitoring Febrile Neutropenia (FEN) in Their Therapeutical Approach…

Primary: Number of Participants With Favorable Clinical Response at End of Inpatient Intravenous Therapy (EOIV) — 41; 36 Participants

Primary: Composite Primary Endpoint: Number of Participants With an Overall Favorable Response to Echinocandin Therapy for Empiric Antifungal Therapy for Persistent Febrile…

Primary: Duration of Grade 3 or 4 Neutropenia (ANC <1.0×10^9/L) in Cycle 1 — 0.68; 0.71 days

Primary: Duration in Days of Grade 4 Neutropenia in Chemotherapy Cycle 1 — 0.2; 0.2 days

Primary: Incidence of Infection — 6 infections

Primary: Percentage of Participants With CSF Prescribed as Primary Prophylaxis — 8.3; 5.5; 7.2; 5.3 percentage of participants — p=0.21

Primary: Grade 3 or 4 Neutropenia — 16; 51 Participants — p=<0.0001

Primary: Number of Participants With Proven/Probable/Possible Invasive Fungal Infection — 1; 0; 2; 62 Participants

Primary: Percentage of Participants With Grade 3/4 Febrile Neutropenia Across the First 4 Cycles of Chemotherapy — 5.7; 2.4 percentage of participants — p=0.014

Primary: Comparison of Cumulative Incidence of Anti-pegfilgrastim Antibodies (Binding and Neutralizing) to Pegfilgrastim Between Treatment Groups at the End of Cycle 4 (Day 84)…

Primary: DSN — 0.15; 0.36; 0.43; 0.29 days

Primary: Relative Change in % pO2 — 12.3; 19; 24; 25.3 change in % oxygenation

Primary: Unplanned Chemotherapy Treatment Delay — 16 Participants

Primary: Mean (SD) Doripenem Pharmacokinetic Volume of Distribution Parameter in Febrile Neutropenic Patients — 36.7; 49.9; 43.9 Liters

Primary: Mean Duration of Grade 4 Neutropenia During Cycle 1 of Chemotherapy — 1.17; 1.2 Days

Primary: Percentage of Participants With Proven or Probable Invasive Fungal Infections (IFI) — 3.1; 7.2 Percentage of participants

Primary: Duration of Neutropenia CTCAE Grade 4 — 0.905; 0.791; 1.725 days

Primary: Duration of Severe Neutropenia (DSN) in Cycle 1 — 0.31; 0.39 Days — p=< 0.0001

Primary: Incidences of Invasive Fungal Diseases (IFD) — 11.76; 10.14; 23.19 percentage of partipants

Primary: Percentage of Participants With Incidence of Vomiting/Retching From Day 1 Through End of Day 5 — 26.3 percentage of particpants

Primary: Duration of Severe Neutropenia (DSN) in Cycle 1 — 1.03; 0.44; 0.03; 0.31 days — p=0.296